Influência do imatinibe no resultado do TMO e sua eficácia no tratamento da recaída

Vigorito, Afonso Celso

doi:10.1590/s1516-84842008000700012

Cited by 1 publication

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This reduces tumoral proliferation, and also causes the blocking of the various cellular signaling routes activated by the protein. Imatinib has shown long-lasting effects during the chronic phase of CML [4] ; however the same results have not been obtained when the treatment was used in more advanced phases of the disease, such as the acute phase and the blast crisis [11] .…”

Section: Imatinibmentioning

confidence: 97%

“…In patients with CML, the dendritic cells can stimulate the NK cells by increased expression of NKG2D ligands [21] . Imatinib seems to prejudice the process of differentiation of dendritic cells in vitro, resulting in cells that do not respond to the maturation stimulus, and do not develop either the primary response of T lymphocytes, or the response of T lymphocytes to antigens [9,11] .…”

Section: Imatinibmentioning

confidence: 99%

See 1 more Smart Citation

Immunological implications of the use of tyrosine kinase inhibitors in chronic myeloid leukemia

et al. 2012

View full text Add to dashboard Cite

Background: The treatment of chronic myeloid leukemia (CML) employs drugs known as tyrosine kinase inhibitors (TKIs). Comparative analyses of the effects of different TKIs has shown that these substances can reduce the immunogenicity of leukemic cells, and prejudice anti-tumoral immunity. Once the TKIs differ in terms of their direct influence on cells of the immunological system, the objective of this work was therefore to analyze alterations in the immunological systems of CML patients using different TKI drugs. Methodology/Principal findings:A review of the literature revealed that imatinib is considered to be the new paradigm for treatment of CML; however, use of this drug can result in inhibition of activation of immune system cells and development of resistance. Second and third generation TKIs can be used in the treatment of patients resistant to imatinib, but can have immunosuppressor effects. Nilotinib is more effective than imatinib in recently-diagnosed patients, however at high doses can induce myelosuppression and diminish cytokine production. Dasatinib was found to induce a rapid full cytogenetic response, with heightened in vivo immune-stimulation, in contrast to an immunosuppression observed in vitro. The mutated T315I phenotype of CML only shows a response to treatment with inhibitors that do not compete with ATP, involving aurora kinases that control mitosis, progression of the cellular cycle, and apoptosis induction. MK0457, which is able to act in the presence of the mutation, presents important bone marrow toxicity, while in small doses danusertib has shown anti-proliferative and pro-apoptotic activity against a wide spectrum of BCR-ABL-positive cells.Conclusions/Significance: Selection of the most suitable tyrosine kinase inhibitor in patients showing positive to the BCR-ABL mutation requires previous analysis of the phenotype and the influence of the TKI on the immunological system.

show abstract

Section: Imatinibmentioning

confidence: 97%